ASCO Reading Room 05.31.2018 — A new blood test appears to detect expression of the programmed death-ligand 1 (PD-L1) protein in circulating tumor cells (CTCs) with high sensitivity, enabling repeat testing to monitor a patient’s response to immunotherapy throughout the course of treatment. The test is able to capture CTCs for PD-L1 testing i...
NEW YORK (360Dx) – CellMax Life announced this week that it is beginning a new clinical trial, which will further validate its circulating tumor cell (CTC) colorectal cancer screening test in American subjects, with the goal of supporting a submission for approval by the US Food and Drug Administration. The study is being conducted with...
SUNNYVALE, Calif., May 30, 2018 /PRNewswire/ — CellMax Life, a leading cancer diagnostics company enabling early cancer detection with affordable non-invasive blood tests, today announced it is commencing Zenith, a U.S. clinical study for its circulating tumor cell (CTC) blood test, which can transform the way colorectal cancer is dete...
May 2018 | Laboratory Economics CellMax Life (Sunnyvale, CA) has already been marketing its blood test for the early detection of colon cancer in Asia for the past two years and plans to o er it in the U.S. market as a laboratory-developed test within the next few months, according to CEO Atul Sharan. Download the...
Apr 10, 2018 | NEW YORK (GenomeWeb) CellMax Life and IncellDx said today that they have signed an agreement to jointly develop and market circulating tumor cell tests across multiple solid tumors and indications, including personalized therapy selection and monitoring. Under the agreement, CellMax will combine its technology for CTC isolation with ...
SUNNYVALE, CALIF. (PRWEB) MARCH 28, 2018 CellMax Life, a leading cancer diagnostics company enabling early cancer detection with affordable non-invasive blood tests, announced today the U.S. launch of a blood test to detect the expression of PD-L1 – a key protein involved in suppressing the immune system – in circulating tumor cells (CTCs). Since i...
Wall Street Journal, March 16, 2018 7:30 a.m. ET Theranos Inc.’s fall underscores the need for medical startups to be transparent in their dealings with investors and to publish data supporting their technology to gain credibility, venture capitalists and entrepreneurs said. Theranos, formed in 2003, climbed to a valuation of more than $9 billion, ...
This study showed that the CellMax CTC blood test can predict which patients in the gray zone will need/have a positive prostate biopsy with a much lower false positive rate than current standard of care tests, potentially reducing unnecessary biopsies in this group by up to 90 percent....
A new, noninvasive blood test can reliably detect prostate cancer in patients with inconclusive PSA tests, the test’s developer, CellMax Life, recently announced. Researchers say the company’s circulating tumor cell (CTC) blood test could reduce the number of unnecessary biopsies by up to 90 percent....
Wall Street Journal highlights CellMax Life’s circulating tumor cell (CTC) as a proven blood testing platform to detect cancer early…. beyond standard DNA sequencing on the Illumina platform. ...